LYTIR

Insider · SEC Form 4 · 10% Owner

Venrock Healthcare Capital Partners III, L.P.

In the 12 months to Nov 19, 2026, on the open market: bought $38.5M of LYCA. Filed a median of 1 business day after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

Insider purchases and sales, by month (last 12 months)Insider purchases: $38.5M in total; Insider sales: $0 in total.Oct: Insider purchases $38.3MNov: Insider purchases $224KDecJanFebMarAprMayJunJulAugSepOctNov$38.3M
Insider purchases above the line: $38.5MInsider sales below: $0
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.
  1. LYCABought: Lycia Therapeutics, Inc. Nov 2, 2026 8,305 shares filed Nov 4, 2026 6,858,542 shares held indirectly after, as filed filing $224K
  2. LYCABought: Lycia Therapeutics, Inc. Oct 30, 2026 9,004 shares filed Oct 30, 2026 2 transactions filing $237K
  3. LYCABought: Lycia Therapeutics, Inc. Oct 29, 2026 1,000 shares filed Oct 30, 2026 6,841,233 shares held indirectly after, as filed filing $26K
  4. LYCABought: Lycia Therapeutics, Inc. Oct 28, 2026 15,000 shares filed Oct 30, 2026 2 transactions filing $382K
  5. LYCABought: Lycia Therapeutics, Inc. Oct 27, 2026 39,796 shares filed Oct 27, 2026 2 transactions filing $1.1M
  6. LYCABought: Lycia Therapeutics, Inc. Oct 26, 2026 1,952,705 shares filed Oct 27, 2026 2 transactions filing $35.2M
  7. LYCABought: Lycia Therapeutics, Inc. Oct 23, 2026 52,939 shares filed Oct 27, 2026 2 transactions filing $1.4M

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. KRROVenrock Healthcare Capital Partners III, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Korro Bio, Inc. filing 9.9%
  2. VORVenrock Healthcare Capital Partners III, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: VOR BIOPHARMA INC. filing 9.9%
  3. XFORVenrock Healthcare Capital Partners III, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: X4 Pharmaceuticals, Inc. filing 7.6%
  4. CBIOVenrock Healthcare Capital Partners III, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Crescent Biopharma, Inc. filing 5.9%
  5. JBIOVenrock Healthcare Capital Partners III, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Jade Biosciences, Inc. filing 5.9%
  6. ACHVVenrock Healthcare Capital Partners III, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Achieve Life Sciences, Inc. filing 5.2%
  7. HELPVenrock Healthcare Capital Partners III, L.P. filed Nov 16, 2026 Schedule 13G/A passive issuer: Helus Pharma Inc. filing 3.5%
  8. LYCAVenrock Healthcare Capital Partners III, L.P. filed Oct 30, 2026 Schedule 13G passive issuer: Lycia Therapeutics, Inc. filing 11.9%
  9. ENTXVenrock Healthcare Capital Partners III, L.P. filed Oct 30, 2026 Schedule 13G passive issuer: Entera Bio Ltd. filing 5.1%
  10. FLSCVenrock Healthcare Capital Partners III, L.P. filed Oct 27, 2026 Schedule 13G passive issuer: Frazier Life Sciences Acquisition Corp. II filing 9%
  11. XFORVenrock Healthcare Capital Partners III, L.P. filed Sep 21, 2026 Schedule 13G passive issuer: X4 Pharmaceuticals, Inc. filing 5.6%
  12. CYCNVenrock Healthcare Capital Partners III, L.P. filed Sep 15, 2026 Schedule 13D may seek influence 4,552,277 shares issuer: Korsana Biosciences, Inc. filing 9.9%
  13. APGEVenrock Healthcare Capital Partners III, L.P. filed Sep 8, 2026 Schedule 13D/A may seek influence 0 shares issuer: APOGEE THERAPEUTICS, INC. filing 0%
  14. VORVenrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: VOR BIOPHARMA INC. filing 9.9%
  15. JBIOVenrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: JADE BIOSCIENCES, INC. filing 8.3%
  16. ORKAVenrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: ORUKA THERAPEUTICS, INC. filing 7.4%
  17. TENXVenrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: Tenax Therapeutics, Inc. filing 4.7%
  18. ANLVenrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: Adlai Nortye Ltd. filing 4.4%
  19. ARTVVenrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: ARTIVA BIOTHERAPEUTICS, INC. filing 4.2%
  20. Venrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: KalVista Pharmaceuticals, Inc. filing 0%
  21. ENGNVenrock Healthcare Capital Partners III, L.P. filed Aug 14, 2026 Schedule 13G/A passive issuer: enGene Holdings Inc. filing 0%

Other Form 4 entries

Not counted above: entries this filer reported on Form 4 in the same 12 months that are not open-market purchases or sales. Each entry is one line of a filing.

  • LYCA: conversion (code C), 1 entry, Oct 26, 2026
Code C
A conversion of a derivative security, such as preferred stock or units, into shares.

Source: the same SEC Form 4 filings. The codes are the SEC's own transaction codes; the meanings above are a plain-words reading of the SEC's Form 4 instructions.